Engineered immune cells take on Platinum-Resistant ovarian cancer

NCT ID NCT07489287

Recruiting now Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an extra boost (IL-18) to help it work. The study will enroll 18 adults and focus on finding a safe dose and understanding side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GB-5267, a type of immune cell (CAR T cell) engineered to target cancer cells and boosted with IL-18
What this could lead to: If successful, this could point toward a new treatment option for ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early, small phase 1 trial with only 18 participants, so safety and dosing are the main focus—not yet proof of effectiveness. There are also risks from the cell therapy itself, such as severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLATINUM-RESISTANT OVARIAN CANCER

Contacts and locations

Locations

Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.